甲磺酸帕珠沙星氯化钠注射液与质子泵抑制剂配伍稳定性研究

    Compatible Stability of Pazufloxacin Mesylate Sodium Chloride Injection and Proton Pump Inhibitors

    • 摘要: 目的 分析甲磺酸帕珠沙星氯化钠注射液与质子泵抑制剂的配伍稳定性。方法 室温(25℃)条件下考察甲磺酸帕珠沙星氯化钠注射液分别与注射用奥美拉唑钠、注射用泮托拉唑钠和注射用兰索拉唑配伍后放置0,2,4,6,8 h的外观及pH值变化;采用HPLC和分光光度法测定含量和溶血率。结果 甲磺酸帕珠沙星氯化钠注射液与注射用奥美拉唑钠、注射用泮托拉唑钠和注射用兰索拉唑配伍后立即发生颜色变化并且随着配伍时间延长逐渐形成沉淀,配伍后溶液的pH值有明显变化,甲磺酸帕珠沙星氯化钠注射液的含量分别降为83%,76%和83%,溶血率明显增加。结论 甲磺酸帕珠沙星氯化钠注射液与注射用奥美拉唑钠、注射用泮托拉唑钠和注射用兰索拉唑存在配伍禁忌,因此甲磺酸帕珠沙星氯化钠注射液不能与质子泵抑制剂类药物同容器配制,如需联合使用时应在使用前后冲洗输液管路。

       

      Abstract: OBJECTIVE To analyze the compatible stability of pazufloxacin mesylate sodium chloride injection with proton pump inhibitors. METHODS Appearances and pH changes of the solution containing pazufloxacin mesylate sodium chloride injection and omeprazole, pantoprazole and lansoprazole were observed at room temperature(25℃) for different period. HPLC was adopted to determine the content. Spectrophotometric method was used to determine hemolytic rate. RESULTS The color of pazufolxacin sodium chloride injection changed immediately when mixing with proton pump inhibitors, and gradually formed precipitation. When two drugs were mixed, the pH values of mixtures were changed obviously, and the contents of pazufloxacin mesylate were decreased by 83%, 76% and 83%, respectively. The hemolytic rates of the mixtures were increased with the time increasing. CONCLUSION It is unstable of the solution containing pazufloxacin mesylate sodium with omeprazole sodium, pantoprazole sodium or lansoprazole. Pazufloxacin mesylate sodium chloride injection should not be used with any proton pump inhibitors in the same infusion container, and the infusion tube should be washed before and after using above drugs.

       

    /

    返回文章
    返回